Yearbook of Intensive Care and Emergency Medicine 2010

Yearbook of Intensive Care and Emergency Medicine 2010

von: Jean-Louis Vincent

Springer-Verlag, 2010

ISBN: 9783642102868 , 602 Seiten

Format: PDF, OL

Kopierschutz: Wasserzeichen

Windows PC,Mac OSX geeignet für alle DRM-fähigen eReader Apple iPad, Android Tablet PC's Online-Lesen für: Windows PC,Mac OSX,Linux

Preis: 117,69 EUR

  • CURED I - LENT Late Effects of Cancer Treatment on Normal Tissues
    Atherosclerosis and Oxidant Stress: A New Perspective
    Medical Technologies in Neurosurgery
    Atlas of Upper Gastrointestinal and Hepato-Pancreato-Biliary Surgery
    Epiphyseal Growth Plate Fractures
    Praxis der Viszeralchirurgie - Gastroenterologische Chirurgie
  • Cell Signaling in Vascular Inflammation
    Mammakarzinom - Operative Behandlungskonzepte
    Brain Metastases
    Clinical Atlas of Interstitial Lung Disease
    Cardiology in Family Practice - A Practical Guide
    Thyroid Disease - A Case-Based and Practical Guide for Primary Care
 

Mehr zum Inhalt

Yearbook of Intensive Care and Emergency Medicine 2010


 

Title Page

2

Copyright Page

3

Table of Contents

4

List of Contributors

8

Common Abbreviations

19

I The Microcirculation

20

The Microcirculation and Oxidative Stress

21

Introduction

21

Reactive Oxygen Species

21

Sources of ROS in the Microcirculation

23

Mitochondria

23

NADPH Oxidase

23

NO Synthase

24

Xanthine Oxidase

24

Other Sources of Superoxide Anion Production

25

Interactions of ROS with the Microcirculation

25

Leukocyte-endothelial Cell Adhesion

26

Vascular Tone Regulation

27

The Vast Spectrum of Intracellular Targets for ROS

27

Role of Oxidative Stress in Microcirculatory Dysfunction

28

Ischemia-reperfusion

28

Sepsis

29

Conclusion

31

References

31

Diagnosis and Treatment of the Septic Microcirculation

34

Introduction

34

Normal Microcirculation

34

The Microcirculation in Sepsis

36

Bedside Study of the Microcirculation

37

The Microcirculation in Distributive Shock

37

Recruiting the Microcirculation Network During Distributive Shock

41

Conclusion

42

References

43

Targeted Treatment of Microvascular Dysfunction

45

Introduction: Microvascular dysfunction is the Root Cause of Inflammatory Organ Dysfunction

45

Traditional Therapies and Biomarkers have Centered on the Macrocirculation

45

New Methods of Assessing the Microcirculation

46

Therapeutic Approaches

47

Suppression of Intracellular Inflammatory Signaling

47

Other inhibitors of cellular inflammation

48

Suppression of Circulating Mediators of Inflammation

49

Large scale removal by hemofiltration

49

Intravenous immunoglobulin

49

Neutralizing antibodies

49

Coagulation

50

Conclusion

50

References

51

II Hemodynamic Monitoring

54

Diagnosing Hypovolemia in Critically Ill Patients

55

Introduction

55

Defining Hypovolemia

55

Diagnosing Hypovolemia

55

Static Diagnostic Tests

56

Dynamic Diagnostic Tests

56

Fluid challenge

56

Arterial waveform-derived variables

56

Passive leg raising

58

Perspective

59

Conclusion

60

References

60

Measuring Stroke Volume Using Electrical Impedance Tomography

62

Introduction

62

Why do we need Non-invasive Cardiovascular Measurements?

62

Electrical Impedance Tomography

63

EIT-based Methods to Measure Stroke Volume

64

Holding the Breath

64

EKG Gating

64

Optimized Separation in the Temporal and Spatial Domains

65

Contrast Agents

66

Deriving Stroke Volume from Cardiac Impedance Images

67

Impedance-time Curves

68

Parametric EIT

69

Conclusion

69

References

70

Direct Arterial Pressure Monitoring: Pattern Recognition in the Management of Circulatory Failure

72

Introduction

72

Case Study 1: Components of an Arterial Pressure Waveform

72

Case Study 2: Hypovolemia

73

Case Study 3: Pulse Pressure as a Measure of Stroke Volume

74

Case Study 4: Effect of Aortic Capacitance on Pulse Pressure

75

Case Study 5: Effect of Vasoconstrictor Drugs on Pulse Pressure

75

Case Study 6: Effect of Vasoconstriction on the Dicrotic Notch and Secondary Pressure Waves

76

Case Study 7: Sympathetic Stimulation and Reflected Pressure Waves

77

Conclusion

78

References

78

Choosing Patient-tailored Hemodynamic Monitoring

80

Introduction

80

What Do We Have and What Can they Do?

80

Factors Affecting Choices

83

Conclusions and Perspective

85

References

85

III Resuscitation Issues

88

Airway and Ventilation during CPR

89

Introduction

89

Regurgitation and Aspiration after Cardiac Arrest

89

The Pros and Cons of Tracheal Intubation

90

Advantages of Tracheal Intubation

90

Disadvantages of Tracheal Intubation

90

Reducing the Risk of Unrecognized Esophageal Intubation

91

Supraglottic Airway Devices

91

Ventilation during CPR

92

Passive Oxygen Insufflation

92

Mouth-to-mouth Ventilation

93

Conclusion

93

References

94

The Role of Gasping in Resuscitation

97

Introduction

97

The Frequency of Gasping in Global Ischemic Events

98

The Meaning of Gasping in Global Ischemic Events

99

The Unique Physiology of Sudden Circulatory Collapse

100

Gasping as an Independent Factor for Improving Survival

102

Improved Airflow, Blood Flow, or Both?

103

Using Gasps to Avoid the Detriments of Positive Pressure Breaths

104

Better Detection of Cardiac Arrest Using Gasps

105

The Role of Gasping in Trauma Care and Infant Resuscitation

106

Creating Gasps for Those Who Do Not Do So

107

Conclusion

107

References

107

Recent Concepts in Burn Resuscitation

110

Introduction

110

Resuscitation Perspectives

110

Can Metabolic Markers Guide Resuscitation and Help Predict Outcomes?

112

Military Resuscitation Experience (Tables 1 and 2)

114

Nurse-driven Resuscitation

116

Consensus Statements

118

Conclusion

119

References

119

Intra-aortic Balloon Counterpulsation in Cardiogenic Shock

121

Introduction

121

What do the Guidelines tell Us and What about ‘Real Life’?

122

Does Hemodynamic Improvement Improve Prognosis in Infarction-triggered Cardiogenic Shock?

122

Effects of IABP on Hemodynamics, Systemic Inflammation and MOF in Infarction-triggered Cardiogenic Shock

124

What Does a Meta-Analysis Tell Us?

125

Beyond IABP: Do We Have Better Alternatives for the Treatment of Cardiogenic Shock?

127

Impella® Pump

127

Extracorporeal Membrane Oxygenation (ECMO)

127

Tandem Heart®

128

Assisted Extracorporeal Life-support in Adults with In-hospital Cardiac Arrest

128

IABP versus Percutaneous LVAD in Cardiogenic Shock: A Meta-analysis

128

We Should Change the Guidelines for IABP Use in Infarction-triggered Cardiogenic Shock!

128

Intra-aortic Balloon Counterpulsation in Septic Shock?

129

Conclusion

131

References

131

IV Inflammatory Responses in the Lung

133

Vascular Endothelial Growth Factor in Acute Lung Injury

134

Introduction

134

Biology of VEGF

134

VEGF Receptors

135

Cellular Source of VEGF within the Lung

135

Cellular Actions of VEGF

135

VEGF as a Pathophysiological Driver of Acute Lung Injury?

136

VEGF Compartmentalization in Acute Lung Injury

137

Tissue Studies

137

Regulation of VEGF Bioactivity

138

Is there a Unifying Hypothesis for the Role of VEGF in Acute Lung Injury?

138

Conclusion

138

References

140

Role of CD14 in Lung Inflammation and Infection

142

Introduction

142

CD14 and the LPS Receptor Complex

144

CD14 and other Pattern Recognition Receptors

145

Role of CD14 in LPS- and LTA-induced Lung Inflammation

146

Role of CD14 in Lung Infection

148

Conclusion

151

References

151

V Mechanical Ventilation

154

Measurement of Functional Residual Capacity during Mechanical Ventilation

155

Introduction

155

Methods for FRC Measurement During Mechanical Ventilation

156

Closed Circuit Techniques

156

Open Circuit Wash-in/washout Procedures

159

Respiratory Inductive Plethysmography

161

Computed Tomography Scan

162

Conclusion

162

References

163

New and Conventional Strategies for Lung Recruitment in Acute Respiratory Distress Syndrome

166

Introduction

166

Definition and Factors Affecting Recruitment Maneuvers

167

Nature and Extent of Lung Injury

168

Patient Positioning

168

Types of Recruitment Maneuver

169

Impact of Recruitment Maneuver on Ventilator-induced Lung Injury

169

The Role of Variable Ventilation as a Recruitment Maneuver

171

Conclusion

172

References

173

Consequences of Pleural Effusions for Respiratory Mechanics in Ventilated Patients

176

Introduction

176

Origin of Pleural Effusions in the Critically Ill Patient

176

Modeling the Pleural Effusion-lung Interaction

177

Pleural Effusion and Respiratory Mechanics

178

Effects of Pleural Effusion on Gas Exchange

180

Practical Implications for the Mechanically Ventilated Patient with Pleural Effusion

181

Pleural Effusions and Ventilator-induced Lung Injury?

183

Conclusion

184

References

184

Weaning Failure of Cardiac Origin: Recent Advances

187

Introduction

187

Mechanisms Contributing to the Development of Weaning-induced Pulmonary Edema

187

Diagnosis of Weaning-induced Pulmonary Edema

188

Clinical Context

188

Right Heart Catheterization

188

Transthoracic Echocardiography

189

Cardiac Biomarkers

190

Detection of Weaning-induced Hemoconcentration

191

Therapeutic Options

192

Conclusion

193

References

193

VI Respiratory Failure

195

The Effects of Pleural Effusion

196

Introduction

196

Pathogenesis

196

Effects of Acute Pleural Effusion on Lung Volume, Respiratory System Mechanics, and Gas Exchange

197

Effects of Thoracentesis on Lung Volume, Respiratory System Mechanics, and Gas Exchange

198

Pleural Effusion in Patients with ALI/ARDS

200

Conclusion

201

References

202

Fluid Management in Acute Lung Injury and ARDS

204

Introduction

204

The Consequences of Pulmonary Edema during ARDS

204

ARDS: Lesional or Hemodynamic Edema?

205

Resorption and Drainage of Pulmonary Edema

207

Fluid Restriction and Diuretics: Clinical Studies and Practical Consequences

207

Modulation of Oncotic or Osmotic Pressure: The Effects of Administering Albumin or Hypertonic Saline

209

Increasing Resorption of Alveolar Edema – A Complementary Objective

211

Conclusion

211

References

211

Life-threatening Respiratory Failure from H1N1 Influenza: Lessons from the Southern Cone Outbreak

214

Introduction

214

Why was Pandemic (H1N1) 2009 Flu So Prevalent in the Southern Cone?

214

How Big was the Outbreak?

215

Common Complications of Influenza

216

Risk Factors for the Acquisition of Severe H1N1 2009 Primary Influenza Pneumonia

218

Differences Comparing this Pandemic with the usual Seasonal Flu

218

Management

218

Non-pharmacologic Therapy

219

Ventilatory settings

219

Recruitment maneuvers

220

Prone position ventilation

220

Adjunctive therapies to mechanical ventilation

221

Pharmacologic Therapy

221

Antivirals

221

Antibacterial antimicrobials

222

Corticosteroid therapy

222

Complications

222

Bacterial Infection

222

Pulmonary Embolism

223

Extrapulmonary Manifestations

223

Renal Failure

223

Cryptogenic Organizing Pneumonia

223

Prognostic Factors for Fatal Influenza Pneumonia

224

Preventive Measures

224

Conclusion

224

References

225

VII Infections

227

Cytomegalovirus Infections in Non-immunocompromised Critically Ill Patients

228

Introduction

228

Clinical Studies

228

Conclusion

231

References

231

Prevention of Central Venous Catheter-related Infection in the Intensive Care Unit

232

Introduction

232

Catheter Care Protocols

233

Staff Educational/Quality Improvement Program

233

Type of Catheter

234

Catheter Insertion Site

235

Ultrasound-guided Placement

236

Insertion Technique

236

Skin Antisepsis

236

Antibiotic Prophylaxis

237

Tunneling

238

Dressing

238

Venous Line Maintenance

239

Conclusion

240

References

241

Standardization of Care to Improve Outcomes of Patients with Ventilator-associated Pneumonia and Severe Sepsis

244

Introduction

244

Prevention and Treatment of VAP

244

Severe Sepsis and Septic Shock

248

Conclusion

250

References

250

Strategies for Implementation of Evidence-based Guidelines for Prevention of Healthcare-associated Infection

253

Introduction

253

Guidelines

253

Adherence to Guidelines

254

Barriers

255

Facilitators

256

Theories of Change

256

Implementation Research

257

Implementation Interventions and Strategies

257

Short Historical Overview

258

The 1990s

258

The 2000s

258

Current insights

259

Implementation of Infection Prevention Guidelines

259

Interventional studies

259

Systematic review

260

Evaluating the Implementation

262

Cost Considerations

262

Conclusion

263

References

263

Antibiotic Stewardship: Possibilities when Resources Are Limited

266

Introduction

266

STEP 1-Include the Antibiotic Stewardship Program within the Hospital Infection Control Program

266

STEP 2-Be Aware of the Different Antibiotic Stewardship Program Strategies

268

STEP 3-Define the Core Strategy/Key Antibiotics/Areas to Include within the Antibiotic Stewardship Program According to the Institution’s Resources

272

STEP 4-Develop and Define Institution-adapted Antibiotic Stewardship Program Performance Indicators

274

Conclusion

274

References

275

VIII Metabolic Support

279

Vitamin D in Critical Illness

280

Introduction

280

Historical Perspective

280

Circadian Rhythm of Vitamin D

281

Pleiotropic Effects of Vitamin D

281

Vitamin D and the Musculoskeletal System

281

Vitamin D and Cardiovascular Disease

283

Vitamin D and the Immune System

283

Vitamin D and Sepsis

284

Miscellaneous Effects of Vitamin D

285

Vitamin D in Critical Illness

285

Challenges for the Intensivist

285

References

286

IX Anticoagulant Therapies

289

Update on Antithrombin for the Treatment of Burn Trauma and Smoke Inhalation Injury

290

Introduction

290

Antithrombin

291

Therapeutic Effects of Antithrombin

291

Anticoagulant Effects

292

Anti-inflammatory effects dependent on the coagulation system

292

Coagulation-independent anti-inflammatory effects

292

Interactions with Heparin

294

Antithrombin for the Treatment of Burn Trauma and Smoke Inhalation Injury

295

Experimental Studies

295

Clinical Studies

297

Conclusion

299

References

299

Update on Physiological Anticoagulant Factor Concentrates in Patients with Sepsis

302

Introduction

302

Inflammation-induced Effects on Physiological Anticoagulant Factors

302

The Antithrombin System

303

The Thrombomodulin-protein C System

304

Tissue Factor Pathway Inhibitor

305

Effects of Natural Anticoagulant Systems on Inflammation

305

Clinical Application of Natural Anticoagulant Factor Concentrates

307

Antithrombin Concentrate

307

Recombinant Human Activated Protein C

308

Soluble Thrombomodulin

311

Recombinant Tissue Factor Pathway Inhibitor

311

Conclusion

312

References

312

X Anemia and Blood Transfusions

315

Venous Oxygen Saturation as a Physiologic Transfusion Trigger

316

Introduction

316

Venous Oxygen Saturation as a Physiologic Transfusion Trigger

316

The Concept of Physiologic Transfusion Trigger

320

Conclusion

322

References

322

Tissue Protective Activities of Erythropoietin

324

Introduction

324

EPO and Tissue Protection

325

Tissue Protection and Clinical Trials

326

Erythropoiesis versus Tissue Protection

327

Conclusion

328

References

329

XI Renal Disease and Therapy

332

Doppler-Based Renal Resistive Index: A Comprehensive Review

333

Introduction

333

Technique

334

Physiological Significance of the Renal Resistive Index

335

Doppler-Based Renal Resistive Index in Selected Renal Diseases

336

Non-obstructive Renal Diseases

336

Obstructive Renal Diseases

336

A Promising Tool in Critically Ill Patients?

337

Conclusion

337

References

338

Atrial Natriuretic Peptide in Postoperative Acute Renal Failure

341

Introduction

341

The Discovery of the Atrial Natriuretic Peptide System

341

Renal Effects of ANP in Humans

342

Renal Blood Flow

342

Glomerular Filtration Rate

342

Tubular Effects of ANP

342

Effects of ANP on Renal Oxygen Consumption

343

Effects of ANP on Renal Blood Flow and GFR in Postoperative Acute Renal Failure

343

Effects of ANP on Renal Outcome in Acute Renal Failure

344

Effects of ANP in Other Forms of Clinical Acute Renal Failure

347

Cyclosporine-induced Acute Renal failure

347

Liver Transplantation

347

Radiocontrast-induced Nephropathy

347

Meta-Analysis of ANP in the Management of Acute Renal Dysfunction

347

Conclusion

348

References

348

Renal Dysfunction in Chronic Liver Disease

351

Introduction

351

Co-existing Liver and Kidney Disease

351

Serum Creatinine Concentration for the Assessment of Kidney Function in Chronic Liver Disease

353

Acute Kidney Injury Network Criteria for staging Acute Kidney Injury

354

Acute Kidney Injury Pathogenesis

355

Patients with Chronic Liver Disease are more Susceptible to Acute Kidney Injury

355

Hepatorenal Syndrome

356

Acute Kidney Injury and Chronic Liver Disease

357

Biomarkers of AKI

358

Kidney Disease Outcome Quality Initiative Criteria for Staging Chronic Kidney Disease

358

Assessment of Chronic Kidney Disease in Patients with Chronic Liver Disease

361

Future Directions

361

Orthotopic Liver Transplantation

362

Conclusion

363

References

364

Hemofiltration and Hybrid Therapies in 2010

367

Introduction

367

Mechanisms of Removal and Transport by Synergistic Action of HVHF and Enhanced Adsorption

368

Synergistic action of HVHF and Enhanced Adsorption: Clinical Feasibility and Effects beyond Hemodynamics

368

New Pathophysiological Insight regarding Septic Acute Kidney Injury

370

Update on Very Recent Trials in Critically ill Patients with AKI

371

Conclusion

372

References

372

Timing of Renal Replacement Therapy

375

Introduction

375

AKI: An Historical Overview

375

A Problem of Uremia

375

The Concept of Prophylactic Dialysis

376

From Acute Renal Failure to AKI, and from Renal Replacement Therapy to Renal Support: A Paradigm Shift

376

Definition of Timing of Initiation of RRT in ICU Patients

378

What does the Evidence tell Us?

378

Urea

378

Volume overload

378

Early initiation in the course of AKI

378

Future Directions: Early Goal-directed Therapy to Improve Renal Outcome

379

Conclusion

379

References

380

XII Neurological Aspects

382

Multimodal Monitoring: A Critical Tool in the Neuro-ICU

383

Introduction

383

Multimodal Monitoring in Hypoxic-Ischemic Encephalopathy

384

Multimodal Monitoring in Traumatic Brain Injury

385

Multi-modal Monitoring in Cerebrovascular Disease

387

Conclusion

389

References

390

Hemodynamic Management of Acute Spinal Cord Injury

392

Introduction

392

Overview of the Incidence and Pathophysiology of Acute Traumatic Spinal Cord Injury-induced Cardiovascular Dysfunction

392

Blood Pressure Augmentation in Patients with Acute Traumatic Spinal Cord Injury

393

Spinal Cord Perfusion Pressure, Intrathecal Pressure, and Treatment

395

Potential Risks of Blood Pressure Augmentation in Acute Spinal Cord Injury

396

Conclusion

396

References

397

Quantitative CT Scan and CT-Estimated Brain Specific Gravity in TBI

399

Introduction

399

Quantitative Computed Tomography

400

Quantative CT Study of Non-contused Hemispheric Areas

402

Quantitative CT Study of Contused Hemispheric Areas

405

Interpretation of Estimated Specific Gravity Variation

406

Conclusion

408

References

409

Cerebral Perfusion in Sepsis

411

Introduction

411

Sepsis and the Brain

411

Inflammation and the Brain

411

Effects of Sepsis on the Blood-brain Barrier and the Vascular Endothelium

412

Cerebral Perfusion

413

Cerebral Perfusion Pressure

413

Regulation of Cerebral Perfusion

413

CO2-reactivity

413

Cerebrovascular pressure autoregulation

414

Perfusion and Brain Dysfunction

414

Cerebral ischemia

414

Cerebral perfusion and sepsis-associated delirium

414

Effects of catecholamines on cerebral perfusion in patients with sepsis

415

Conclusion

415

References

416

Systemic Complications after Subarachnoid Hemorrhage

419

Introduction

419

Cardiac Abnormalities

420

Lung Abnormalities

421

Fever

422

Anemia

422

Hyperglycemia

423

Electrolyte Abnormalities

423

Conclusions

425

References

425

XIII Perioperative Management

428

Epidural Anesthesia: New Indications for an Old Technique?

429

Introduction

429

Effects of Epidural Anesthesia on Pain Management

430

Effects of Thoracic Epidural Anesthesia on Myocardial Function

430

Effects of Thoracic Epidural Anesthesia on Pulmonary Function

431

Effects of Thoracic Epidural Anesthesia on Gastrointestinal Function

431

Effects of Thoracic Epidural Anesthesia on the Immune System

432

Effects of Thoracic Epidural Anesthesia on Long-term Outcome

432

Adverse Effects and Potential Risks of Epidural Anesthesia

433

Conclusion

434

References

434

Risk Assessment and Prevention of Perioperative Stroke

437

Introduction

437

Pathophysiology

437

Review of Clinical Studies

439

Preventive Strategies

447

Conclusion: Proposed/useful Clinical Perioperative Guidelines

449

References

450

Overview of Chronic Post-thoracotomy Pain: Etiology and Treatment

453

Introduction

453

Prevalence

453

Pathology

453

Preoperative Factors

454

Demographic Factors

454

Genetics

454

Psychosocial Factors

454

Preoperative Pain

454

Intraoperative Factors

455

Surgery

455

Analgesia

455

Postoperative Factors

455

Others

455

Strategies for Treating Long Term Pain

457

Conclusion

457

References

457

XIV Abdominal Compartment Syndrome

460

The Polycompartment Syndrome: What’s all the Fuss About?

461

Introduction

461

Pathophysiology

461

Orbital Compartment Syndrome

461

Intracranial Compartment Syndrome

464

Thoracic Compartment Syndrome

465

Cardiac Compartment Syndrome

467

Limb or Extremity Compartment Syndrome

469

Hepatic Compartment Syndrome

471

Renal Compartment Syndrome

471

Pelvic Compartment Syndrome

472

Abdominal Compartment Syndrome

472

Monitoring of intra-abdominal pressure

475

Abdominal perfusion pressure measurement

475

Clinical Management

476

Conclusion

477

References

477

Laparostomy: Why and When?

481

Introduction

481

Who Started Laparostomy?

481

Temporary Abdominal Cover

482

Classification of Open Abdomen

483

Definitive Abdominal Wall Closure

483

Does Laparostomy Improve Outcome?

484

Conclusion

486

References

486

XV Drug Distribution and Clearance

488

Augmented Renal Clearance: Unraveling the Mystery of Elevated Antibiotic Clearance

489

Introduction

489

Defining Augmented Renal Clearance

489

Assessing Renal Function in Critical Illness

490

Changes in Critical Illness Contributing to Augmented Renal Clearance

491

Prevalence and Natural History of Augmented Renal Clearance in the Critically Ill

491

Traumatic Brain Injury

492

Surgery and Trauma

493

Burns

493

Hematological Malignancy

493

Hypoalbuminemia

494

What are the Clinical and Dosing Implications of Augmented Renal Clearance?

494

Concentration-dependent Killing

494

Aminoglycosides

494

Time-dependent Killing

495

ß-lactam antibiotics

495

Oxazolidinone antibiotics

496

AUC0–24/MIC antibiotics

496

Glycopeptides

496

Quinolone antibiotics

497

Therapeutic Drug Monitoring

497

Conclusion

498

References

498

Drug Distribution: Is it a more Important Determinant of Drug Dosing than Clearance?

501

Introduction

501

Overview of Pharmacokinetic and Pharmacokinetic/pharmacodynamic Parameters

501

Volume of Distribution versus Clearance: How do they Affect Serum Drug Concentration and Half-life?

502

Causes and Consequences of Increased Volume of Distribution

503

Chronic Increases in Volume of Distribution

504

Obesity

504

Chronic organ dysfunctions

505

Other scenarios

505

Acute Increases in Volume of Distribution

506

Severe sepsis

506

Burns

506

Hypoalbuminemia

506

Other scenarios

507

Measurement of Volume of Distribution in Critically Ill Patients

507

Clinical Significance and Recommended Dose Strategies

507

Conclusion

508

References

508

XVI Risk Stratification

511

Risk Stratification in Severe Sepsis: Organ Failure Scores, PIRO or Both?

512

Introduction

512

Organ Dysfunction/Failure Scores

513

From Multiple Organ Dysfunction/Failure Scores to the PIRO Concept

514

Should We Have One PIRO Or Many PIROs?

517

Should we use PIRO or MOF Scores?

518

References

519

XVII Critical Care Outreach

522

On the Response to Acutely Deteriorating Patients

523

Introduction: The Deteriorating Patient

523

Sub-optimal Care

523

‘Track and Trigger’ Mechanisms

524

Role of Critical Care Outreach Services

525

Educational Tools

526

Use of Technology as a Tool to ‘Track and Trigger’

527

Human Factors

528

Conclusion

529

References

529

Identifying Cardiorespiratory Insufficiency Outside the ICU

531

Introduction

531

Existing Non-invasive Cardiovascular Monitoring is Ineffective at Identifying Instability In Step-down Units

532

Integrated Monitoring Systems to Monitor the Monitors

534

Implications

535

References

535

XVIII End-of-life Issues

536

An Update on ICU Management of the Potential Organ Donor

537

Introduction

537

Role of the Intensivist

537

Physiologic Changes Associated with Brainstem Death

538

Protocols for Management of the Potential Organ Donor

538

Management of Individual Organ Systems

539

Cardiovascular

539

Pulmonary

542

Endocrine

543

Renal and Gastrointestinal

544

Coagulopathy and Hypothermia

544

Donation after Cardiac Death

544

Conclusion

546

References

547

End-of-life Care in the ICU: Commonalities and Differences between North America and Europe

550

Introduction

550

Discrepancy between Preferred and Actual Place of Death

550

Use of Critical Care Services during Terminal Hospitalization

551

Health Care Costs during Terminal Hospitalization

551

Variation in End-of-life Intensive Care Use

551

End-of-life Decision-making Process

552

An American Perspective

552

A European Perspective

554

Unintended Consequences of End-of-life Decision-making

555

Conclusion

556

References

556

XIX Patient Care

559

Do Sleep Disorders have an Impact on Outcome in ICU Patients?

560

Introduction

560

Anesthesia/sedation and Sleep are not Identical, but may Share Common Mechanisms

560

Exploring Sleep in ICU Patients

561

Characteristics of Sleep Alteration in ICU Patients

562

ICU Environment

563

Mechanical Ventilation

564

Drugs

564

Impact of Sleep Disturbance on Patient Outcome

565

Therapeutic Interventions to Preserve/improve Sleep (Table 2)

566

Attenuation of Noise and Light

566

Limiting Interventions

567

Changing to Assist-control or Proportional Assist Ventilatory Modes

567

Use of Pharmacological Interventions

567

Conclusion

568

References

568

Communication in Crisis: The Importance of ‘Verbal Dexterity’

570

Introduction

570

The Importance of Communication and Culture

570

Airway, Breathing, Communication: The New ABCs of Crisis Management

571

“Say what you Mean, and Mean what you Say”

571

Mitigating Speech: “No ifs, and, or Buts”

572

Silence is not always Golden

573

Graded Assertiveness: Getting the Message Across

573

Questioning Authority and Handing Over Responsibility: Underappreciated Skills

574

Practicing Verbal Dexterity

575

Managing Interruptions and Distractions

575

Communication really Ought to have Three Cs

576

Conclusion

576

References

577

Patient Safety and Acute Care Medicine: Lessons for the Future, Insights from the Past

579

Introduction

579

‘The Missing Curriculum’ [3]

579

Engineering and Acute Care Medicine

580

Engineering and Error Prevention

581

Understanding the Basics of Human Error

581

Educating for Safety

582

Maximizing the Best of Human and Machine

583

Other Lessons from the Chessboard

584

Conclusion

584

References

585

Subject Index

586